Garner-Spitzer Erika, Kundi Michael, Rendi-Wagner Pamela, Winkler Birgit, Wiedermann Gerhard, Holzmann Heidemarie, Herzog Christian, Kollaritsch Herwig, Wiedermann Ursula
Department of Specific Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Vienna, Austria.
Vaccine. 2009 Jan 7;27(2):197-204. doi: 10.1016/j.vaccine.2008.10.045. Epub 2008 Nov 7.
We recently published a study on the persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population of 1014 vaccinees. The majority of these vaccinees still exhibited sufficient protective antibody levels, while 2% displayed antibody concentrations below detection level. In order to investigate whether the low antibody levels were due to decline after primary vaccination or due to an intrinsic inability to sufficiently respond to hepatitis A antigen, we sought to recruit these low/no responder vaccinees to characterize their immune responses in more detail after booster vaccination in comparison to high responder vaccinees.
Prior to and one week after booster vaccination with a hepatitis A vaccine, antibody levels, cytokine levels (IL-2, IFN-gamma and IL-10) and CD surface marker expression on peripheral blood mononuclear cells were determined in a study population comprised of 52 individuals. Additionally, the hepatitis A HAV cellular receptor 1 (HAVcr-1) TIM-1, being also expressed on CD4+ T cells and associated with immunomodulatory properties, was measured by RT-PCR before and after hepatitis A booster.
Our data indicate that there is indeed a small group of hepatitis A vaccinees that can be classified as low/no responders as their antibody levels remain below the seroprotection level of 20mIU/ml after booster vaccination. We further describe a good correlation between antibody concentrations and cellular responses, showing that low antibody production is associated with low antigen specific cytokine levels (IL-2, IFN-gamma, IL-10) and vice versa. While there was no significant difference in the expression of the most common surface markers on T and B cells before and after booster vaccination in low and high responder vaccinees, the expression of HAVcr-1 on CD4 T cells correlated significantly with the antibody responses and cytokine levels, suggesting this receptor as cellular prediction marker of immune responsiveness to hepatitis A.
Whether hepatitis A low/non-responders deserve particular attention as a risk group or might display certain resistance to hepatitis A infection due to a lack of the hepatitis A receptor needs further investigations. At this stage we suggest that persons at high exposure risk should be carefully observed.
我们最近发表了一项关于在1014名未经过挑选的疫苗接种者的研究群体中,甲型肝炎初次疫苗接种10年后血清保护持续情况的研究。这些疫苗接种者中的大多数仍表现出足够的保护性抗体水平,而2%的人抗体浓度低于检测水平。为了调查低抗体水平是由于初次接种疫苗后抗体下降还是由于对甲型肝炎抗原的内在反应不足,我们试图招募这些低/无反应疫苗接种者,以便与高反应疫苗接种者相比,在加强免疫后更详细地描述他们的免疫反应。
在由52名个体组成的研究群体中,测定了甲型肝炎疫苗加强免疫前和加强免疫一周后的抗体水平、细胞因子水平(白细胞介素-2、干扰素-γ和白细胞介素-10)以及外周血单个核细胞上的CD表面标志物表达。此外,在甲型肝炎加强免疫前后,通过逆转录-聚合酶链反应(RT-PCR)检测了甲型肝炎病毒细胞受体1(HAVcr-1)TIM-1,其也在CD4+T细胞上表达并具有免疫调节特性。
我们的数据表明,确实有一小部分甲型肝炎疫苗接种者可被归类为低/无反应者,因为他们在加强免疫后抗体水平仍低于20mIU/ml的血清保护水平。我们进一步描述了抗体浓度与细胞反应之间的良好相关性,表明低抗体产生与低抗原特异性细胞因子水平(白细胞介素-2、干扰素-γ、白细胞介素-10)相关,反之亦然。虽然在低反应和高反应疫苗接种者中,加强免疫前后T细胞和B细胞上最常见表面标志物的表达没有显著差异,但CD4 T细胞上HAVcr-1的表达与抗体反应和细胞因子水平显著相关,表明该受体是对甲型肝炎免疫反应性的细胞预测标志物。
甲型肝炎低/无反应者作为一个风险群体是否值得特别关注,或者由于缺乏甲型肝炎受体是否可能对甲型肝炎感染表现出一定的抵抗力,需要进一步研究。在现阶段,我们建议应仔细观察高暴露风险人群。